Levels as of Friday 1 May US close. Sourced from Bloomberg Europe tab; cross-checked against CNBC, Yahoo Finance, FXLeaders, Reuters and FXStreet.
| Instrument | Last | Change |
|---|---|---|
| S&P 500 (cash) | 7,230.12 | +0.29% · 6th wkly gain |
| Nasdaq Composite | 25,114.44 | +0.89% · record |
| Dow Jones Industrial | 49,499.27 | −0.31% |
| FTSE 100 | ~10,180 | pared losses, thin holiday tape |
| Stoxx 600 / DAX | closed | May Day holiday — reopens Mon |
| US 10y Treasury | ~4.40% | below 4.45% post-FOMC |
| EUR/USD | ~1.176 | touched high 1.1767 |
| GBP/USD | ~1.34 | range-bound |
| Brent crude | ~$108.9 | eased on Iran-talks softening |
| WTI crude | ~$106 | 2nd weekly gain risked |
| Gold | near record | geopolitical bid intact |
The Iran war is now the controlling variable for both crude and US foreign policy posture. Friday's tape mixed two contradictory signals: Trump publicly preferring not to strike further, while the US prepared the first combat use of hypersonic weapons against Iranian targets and warned global shippers that paying Hormuz transit tolls to Tehran could trigger US sanctions. The Treasury also sanctioned Iranian exchanges and a Chinese oil terminal involved in shipments. Brent has eased back into the high $100s — well below the March panic peak — but the supply-chain plumbing remains broken.
The European theatre also moved in a substantive way. The 5,000-troop drawdown from Germany, the open question over Italy and Spain, and a US–EU tariff threat on autos all land in the same news cycle. For European industrial earnings, the autos ADRs already telegraphed where the Monday open is heading. For European political risk, the Pentagon move accelerates Berlin and Brussels' security-autonomy debate — defence-equity demand is already pricing this in.
The April FOMC kept policy on hold but with three dissents. Three of the dissenting officials this week tied their position explicitly to rising uncertainty — softer growth on one side, energy- and tariff-driven inflation on the other. Bond traders are now hedging both cuts and hikes, an unusual configuration that maps cleanly onto the steeper long end. The 10y has settled into a 4.40–4.45% range. The Bank of England's sole dissenter publicly pushed for quick rate hikes; the ECB's Makhlouf flagged that upside risks to inflation have intensified. Net: the global central-bank reaction function is rotating hawkish at the margin even as growth wobbles.
Powell's chairmanship is widely expected to end in May; Kevin Warsh remains the consensus successor. Whatever the language at the next meeting, the political optics of any cut into a tariff-driven inflation impulse get materially harder. Today's calendar item to keep filed away: ISM Services on Wednesday, ECB minutes mid-week, and the next round of UK/Japan central-bank speak.
Apple is the through-line. Beat-and-raise on services, the Mac Mini price hike, and the explicit memory-cost commentary keep the AI-hardware bottleneck story alive. The Mac Mini bump is the single cleanest data point of the week — when Apple, of all companies, passes through DRAM cost into a flagship consumer SKU, the squeeze is real and persistent. Hyperscaler capex remains the demand sink; Meta's $19.84bn Q1 capex from earlier in the week and Bloomberg's reporting on AI-fuelled big-tech borrowing are the other side of the same trade.
Around the edges: eBay rallied on a report that GameStop is preparing a takeover bid; Anthropic's Mythos product drew a Fed Governor (Bowman) into commentary on the dynamic nature of AI tools; OpenAI's CFO talked about a "vertical wall of demand"; and the Musk vs OpenAI trial had a difficult first week for the Musk side. Cerebras is reportedly targeting up to a $4bn IPO. The IPO window is, again, open in selective AI infrastructure names.
Two threads relevant to a clinician. First, J&J's ketamine derivative Spravato is now a $1.7bn franchise per Bloomberg's reporting — a meaningful proof-point for the broader interventional-psychiatry pipeline (Seaport's debut on Friday rallied 10% on the same theme). Second, Moderna's CEO commented on flu shots and skin-cancer trial progress; the mRNA platform's oncology read-throughs remain one of the more interesting clinical stories of 2026. Of tangential interest: BMO is using AI and quantum computing to predict earthquakes — a small but growing case study in domain-specific AI deployment beyond LLMs.